CD274 and melanoma: These studies imply that regulatory T cell depletion and use of anti-PD-L1 antibody before culture may increase the success rate in growing tumor-reactive TIL, and potentially expand the use of ACT to greater number of patients with melanoma and potentially other malignancies.